SEMINARS IN THROMBOSIS AND HEMOSTASIS – VOLUME VIII

AUTHOR INDEX

Andrew M, 248
Barr RD, 248
Bermes EW, 288
Bick RL, 69, 156, 263, 276, 288, 302, 331
Blajchman MA, 105
Brain MC, 186
Carter CJ, 198
Clark WF, 138
Collen D, 2
deBoer AC, 161
Edgington TS, 36
Fareed J, 288
Francis CW, 25
Genton E, 161
Gibbons S, 83
Gibson B, 234
Graeff H, 57
Hackett T, 116
Hafter R, 57
Hermans J, 11
Hirsh J, 75
Hunter D, 234
Kelton JG, 83, 116, 217, 234
Klein CA, 105
Lijnen HR, 2
Lindsay RM, 138
Marder VJ, 25
McDonagh J, 11
Messmore HL, 267, 288
Murano G, 69, 156, 263, 331
Neame PB, 75, 186, 217, 234
Ockelford PA, 198
Plow EF, 36
Powers P, 116
Turpie AGG, 161
Walenga JM, 288
Wilson JJ, 217

CUMULATIVE TABLE OF CONTENTS

Number 1
MOLECULAR ASPECTS OF FIBRIN FORMATION AND DISSOLUTION

Interaction of Plasminogen Activators and Inhibitors with Plasminogen and Fibrin, H.R. Lijnen, Ph.D. and D. Collen, M.D., Ph.D., 2

Fibrin: Structure and Interactions, J. Hermans, Ph.D. and J. McDonagh, Ph.D., 11

A Molecular Model of Plasmic Degradation of Crosslinked Fibrin, C.W. Francis, M.D. and V.J. Marder, M.D., 25

Surface Markers of Fibrinogen and Its Physiologic Derivatives Revealed by Antibody Probes, E.F. Plow, Ph.D. and T.S. Edgington, M.D., 36

Detection and Relevance of Crosslinked Fibrin Derivatives in Blood, H. Graeff, M.D. and R. Hafter, Ph.D., 57

Abstracts of Current Literature, 69

Number 2
DISORDERS WITH INCREASED PLATELET DESTRUCTION PART I

Increased Platelet Destruction, P.B. Neame, M.D. and J. Hirsh, M.D., 75

Autoimmune Platelet Destruction: Idiopathic Thrombocytopenic Purpura, J.G. Kelton, M.D. and S. Gibbons, M.B., 83

Alloantibodies and Platelet Destruction, C.A. Klein, M.D., F.R.C.P. (C) and M.A. Blajchman, M.D., F.R.C.P. (C), 105

Drug Induced Platelet Destruction, T. Hackett, M.D., F.R.C.P. (C), J.G. Kelton, M.D., F.R.C.P. (C), and P. Powers, M.D., F.R.C.P. (C), 116

Platelet Destruction in Renal Disease, R.M. Lindsay, M.D. and W.F. Clark, M.D., 138

Abstracts of Current Literature, 156

Number 3
DISORDERS WITH INCREASED PLATELET DESTRUCTION PART II

Platelet Consumption in Cardiovascular Disease, A.G.G. Turpie, M.B., A.C. deBoer, M.D., and E. Genton, M.D., 161

Thrombotic Thrombocytopenic Purpura and the Hemolytic Uremic Syndrome, M.C. Brain, D.M. and P.B. Neame, M.D., 186

Disseminated Intravascular Coagulation: Application and Utility of Diagnostic Tests, P.A. Ockelford, M.D. and C.J. Carter, M.B., 198

Infection-Induced Thrombocytopenia, J.J. Wilson, M.D., P.B. Neame, M.D., and J.G. Kelton, M.D., 217

Thrombocytopenia in Preeclampsia and Eclampsia, B. Gibson, M.B., D. Hunter, M.B., P.B. Neame, M.D., and J.G. Kelton, M.D., 234

Increased Platelet Destruction in Infancy and Childhood, M. Andrew, M.D. and R.D. Barr, M.D., 248

Abstracts of Current Literature, 263

Number 4
ANTITHROMBIN AND FIBRINOGEN DEGRADATION PRODUCTS

Natural Inhibitors of the Coagulation System, H.L. Messmore Jr., M.D., 267

Clinical Relevance of Antithrombin III, R.L. Bick, M.D., 276

Laboratory Evaluation of Antithrombin III: A Critical Overview of Currently Available Methods for Antithrombin III Measurements, J. Fareed, Ph.D., H.L. Messmore, M.D., J.M. Walenga, M.T.(A.S.C.P.), E.W. Bermes, Ph.D., and R.L. Bick, M.D., 288

The Clinical Significance of Fibrinogen Degradation Products, R.L. Bick, M.D., 302

Abstracts of Current Literature, 331